Company: CORT
Filing Date: 2025-05-05
Form Type: 10-Q
Source: 0001628280-25-022173
Chunk: 2

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-05-05
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---
 operating assets and liabilities:Trade receivables(7,843)(20,395)Insurance recovery receivable related to Melucci litigation— 14,000 Inventory605 983 Prepaid expenses and other current assets(13,525)3,612 Other assets— 153 Accounts payable12,929 (4,861)Accrued research and development expenses(8,608)3,494 Accrued and other liabilities(5,939)9,114 Accrued Settlement related to Melucci litigation— (14,000)Long-term accrued income taxes169 562 Operating lease liability(101)(75)Net cash provided by operating activities5,128 23,756 Cash flows from investing activities:Purchases of property and equipment(104)— Proceeds from sales and maturities of marketable securities112,078 68,862 Purchases of marketable securities(115,145)(77,876)Net cash used in investing activities(3,171)(9,014)Cash flows from financing activities:Proceeds from stock option exercises, net of issuance costs1,740 749 Proceeds from purchases under the Employee Stock Purchase Program1,715 940 Repurchases of common stock in connection with Stock Repurchase Program(27,433)(476)Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises and vesting of restricted stock grants(15,825)(1,756)Net cash used in financing activities(39,803)(543)Net (decrease) increase in cash and cash equivalents(37,846)14,199 Cash and cash equivalents, at beginning of period127,665 135,551 Cash and cash equivalents, at end of period$89,819 $149,750 Supplemental disclosure: Exercise cost of shares repurchased for net settlement of cashless option exercises$5,261 $1,798 

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

CORCEPT THERAPEUTICS INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

(In thousands)

Common StockAdditional Paid-in CapitalTreasury StockAccumulated Other Comprehensive (Loss) IncomeRetained EarningsTotal Stockholders’ EquitySharesAmountBalance at December 31, 2024105,113 $136 $832,108 $(696,173)$(